Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | Pharmaceutical Research (Editorial Board)

Pharmaceutical Research

Pharmaceutical Research

An Official Journal of the American Association of Pharmaceutical Scientists

Editor-in-Chief: Peter W. Swaan

ISSN: 0724-8741 (print version)
ISSN: 1573-904X (electronic version)

Journal no. 11095

$199.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 12 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy


Peter W. Swaan, University of Maryland, Baltimore, Maryland, USA



Iñaki Trocóniz, Dept. of Pharmacometrics & Systems Pharmacology, Universidad de Navarra, Spain

Uday Kompella, University of Colorado, Denver, Colorado, USA

Tonglei Li, Purdue University, West Lafayette, Indiana, USA

Hanns-Christian Mahler, Lonza AG, Basel, Switzerland

Tamara Minko, State University of NewJersey–Rutgers, Piscataway, NewJersey, USA

James E. Polli, University of Maryland, Baltimore, Maryland, USA

Ikumi Tamai, Kanazawa University, Kanazawa, Japan

Christine Vauthier, Centre National de la Recherche Scientifique, Paris, France

Ernst Wagner, Ludwig-Maximilians-Universität, Munich, Germany

Yuhong Xu, Shanghai Jiaotong University, Shanghai, China



Sean Ekins, Collaborations in Chemistry, Fuquay-Varina, North Carolina, USA



Joseph Nicolazzo, Monash University, Melbourne, Australia



Bradley D. Anderson, University of Kentucky, Lexington, Kentucky, USA

Per Artursson, Uppsala University, Uppsala, Sweden

Patrick Augustijns, Katholieke Universiteit Leuven, Leuven, Belgium

Reina Bendayan, University of Toronto, Toronto, Canada

Robin H. Bogner, University of Connecticut, Storrs, Connecticut, USA

Kawthar Bouchemal, University Paris Sud, Chaˆtenay-Malabry, France

Youngro Byun, Seoul National University, Seoul, Korea

John F. Carpenter, University of Colorado, Denver, Colorado, USA

Hak Kim Chan, University of Sydney, Sydney, Australia

Paolo Colombo, University of Parma, Parma, Italy

James T. Dalton, University of Michigan, Ann Arbor, Michigan, USA

Elizabeth de Lange, Leiden University, Leiden, The Netherlands

Stephen Duffull, University of Otago, Dunedin, New Zealand

Gert Fricker, Ruprecht-Karls-Universitat Heidelberg, Heidelberg, Germany

Lawrence Gan, Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA

Bruno C. Hancock, Pfizer Inc., Groton, Connecticut, USA

Hideyoshi Harashima, Hokkaido University, Sapporo, Japan

Anthony J. Hickey, RTI International, Research Triangle Park, North Carolina,


Günther Hochhaus, University of Florida, Gainesville, Florida, USA

Ming Hu, University of Houston, Houston, Texas, USA

Wim Jiskoot, Leiden University, Leiden, The Netherlands

Hiroyuki Kusuhara, University of Tokyo, Tokyo, Japan

Glen S. Kwon, University of Wisconsin, Madison, Wisconsin, USA

David Lechuga-Ballesteros, PearlTherapeutics, Inc., Redwood City, California, USA

Claus-Michael Lehr, Saarland University, Saarbrueken, Germany

Dexi Liu, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Junxuan Lu, Texas Tech University, Amarillo, Texas, USA

Zheng-Rong Lu, University of Utah, Salt Lake City, Utah, USA

Panos Macheras, University of Athens, Athens, Greece

Enrico Mastrobattista, Utrecht University, Utrecht, The Netherlands

Ashim Mitra, University of Missouri, Kansas City, Missouri, USA

Marilyn E. Morris, SUNY Buffalo, Buffalo, New York, USA

Emi Nakashima, Kyroitsu University, Tokyo, Japan

Christopher Porter, Monash University, Melbourne, Australia

Mark Prausnitz, Georgia Institute of Technology, Atlanta, Georgia, USA

David Putnam, Cornell University, Ithaca, New York, USA

Wolfgang Sadée, Ohio State University, Columbus, Ohio, USA

Fazlul Sarkar, Wayne University School of Medicine, Detroit, Michigan, USA

Raymond Schiffelers, Utrecht University Medical Center, Utrecht, The Netherlands

Danny Shen, University of Washington, Seattle, Washington, USA

Chang Koo Shim, Seoul National University, Seoul, Korea

Steven J. Shire, Genentech, Inc., San Francisco, California, USA

Shivendra V. Singh, University of Pittsburgh School of Medicine, Pittsburgh,

Pennsylvania, USA

Audra L. Stinchcomb, University of Maryland, Baltimore, Maryland, USA

Yoshinobu Takakura, Kyoto University, Kyoto, Japan

Iñaki F. Trocóniz, University of Navarra, Pamplona, Spain

Dong-an Wang, Nanyang Technological University, Singapore

Hongbing Wang, University of Maryland, Baltimore, Maryland, USA

Kishor M. Wasan, University of British Columbia, Vancouver, Canada

Anthony John Williams, Royal Society of Chemistry, Wake Forest, North

Carolina, USA

J. Andrew Williams, Pfizer Inc., San Diego, California, USA

Steven Wright, University of Arizona, Tucson, Arizona, USA

Wen Xie, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Keiji Yamamoto, Chiba University, Chiba, Japan

Fumiyoshi Yamashita, Kyoto University, Kyoto, Japan

Guofeng You, State University of New Jersey–Rutgers, Piscataway,

New Jersey, USA

Paul Young, University of Sydney, Sydney, Australia

Maciej J. Zamek-Gliszczynski, GlaxoSmithKline, King of Prussia, Pennsylvania

Meet the Editors of PharmRes 

Meet the Editors of PharmRes

Pharmaceutical Research is published under the leadership of a team of dedicated scientists. We invite you to meet the Editors by reading their biographical portraits below.

Peter Swaan, Editor-in-Chief 

Peter Swaan
Peter Swaan is Professor of Pharmaceutical Sciences and Associate Dean of Research and Graduate Studies at the University of Maryland in Baltimore. He received his Ph.D. in biopharmaceutics from Utrecht University in The Netherlands (1993) and did his postdoctoral work at the University of California at San Francisco (1996-2002). After completing his training, Dr. Swaan accepted a faculty position in Pharmaceutics at The Ohio State University (1996-2002).
Dr. Swaan’s research interests are focused on drug transport systems in health and disease. He applies a multidisciplinary approach toward studying the structure and function of transport proteins that includes molecular biology, biophysics, bioconjugate chemistry, and computational modeling. He has a keen interest in the regulation and trafficking of transporters and receptors and their potential role as drug delivery targets. His laboratory is funded by the National Institutes of Health. He has published more than 100 manuscripts, book chapters, and reviews.
Dr. Swaan has been actively involved in the American Association of Pharmaceutical Scientists (AAPS), serving as Vice-Chair, Chair-elect, and Chair of the Pharmaceutics and Drug Delivery Section (2003-2006). He received the AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technology in 2000.

Sean Ekins, Editor, Special Features 

Sean Ekins received his M.Sc., Ph.D., and D.Sc. from the University of Aberdeen. His areas of interest are in vitro and computational ADME/Tox, biomarkers, systems biology, and computational drug discovery. He was a postdoctoral fellow at Lilly Research Laboratories in the drug disposition group and has worked as a senior scientist at Pfizer and Lilly Research Laboratories in the drug-drug interaction screening and computational ADME/Tox groups, respectively. Dr. Ekins was also Associate Director of Computational Drug Discovery at Concurrent Pharmaceuticals, Inc. and Vice President of Computational Biology at GeneGo.
Dr. Ekins is currently Principal Consultant for Collaborations in Chemistry; CSO at Collaborative Drug Discovery Inc.; CSO at the Hereditary Neuropathy Foundation; CEO at Phoenix Nest Inc.; CEO at Collaborations Pharmaceuticals Inc., Adjunct Associate Professor at the School of Pharmacy Department of Pharmaceutical Sciences, University of Maryland; Adjunct Professor in the Department of Pharmacology at Rutgers—Robert Wood Johnson Medical School, Piscataway, NJ; and Adjunct Professor, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.
Dr. Ekins has authored or coauthored more than 230 peer-reviewed papers and book chapters, and he has edited four books. He is on the editorial board of Drug Discovery Today.
Dr. Ekins specializes in drug metabolism, disposition, and molecular pharmacology. His current research interests include biopharmaceutics/molecular biopharmaceutics, in vitro/in vivo methodologies for evaluating drug transport, membrane transport/transporters, structural biology/structure transport activity relationship, transporter-based drug discovery/development/screening, transporter-related drug-drug interaction/adverse reaction toxicity, drug design and synthesis, computer simulation/modeling, pharmacology, bioinformatics, rare disease drug discovery, and infectious disease research.

Uday Kompella, Editor 

Kompella, Author
Uday Kompella is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at the University of Colorado Denver. A key focus of Dr. Kompella’s research is the application of nanotechnology for drug delivery, gene delivery, and imaging. Dr. Kompella is currently applying these technologies to the enhancement of treatment options for diabetic retinopathy, age-related macular degeneration, and cancers. Dr. Kompella has published research in more than 150 scientific papers and book chapters, and he has coedited three books: Nanoparticle Technology for Drug Delivery, Supercritical Fluid Technology for Drug Product Development, and Drug Product Development for the Back of the Eye.
Dr. Kompella received his B.Pharm (Hons) from the Birla Institute of Technology and Science, Pilani, his M.Pharm (Pharmaceutical Engineering) from Jadavpur University, Kolkata, and his Ph.D. in Pharmaceutical Sciences from the University of Southern California, Los Angeles. Before joining the University of Colorado, Dr. Kompella served as a faculty member at the University of Nebraska Medical Center and Auburn University. Dr. Kompella has served as a Chairman of the Regulatory Sciences Section of the American Association of Pharmaceutical Scientists (AAPS), the Books Editorial Advisory Group of the AAPS, the Ocular Drug Delivery and Disposition Focus Group of the AAPS, and the Pharmaceutical Sciences Graduate Program at the University of Nebraska Medical Center. Dr. Kompella is a recipient of the New Investigator Grant in Pharmaceutics and Pharmaceutical Technologies from the AAPS, an Undergraduate Teaching Excellence Award from the Alumni Association of Auburn University, Distinguished Scientist and Distinguished Teacher awards from the University of Nebraska Medical Center, a Dean’s Mentoring Award from the University of Colorado Anschutz Medical Campus, and an ARVO Foundation/Pfizer/Carl Camras Translational Research Award in Ophthalmology from ARVO. Dr. Kompella is a Fellow of the AAPS and ARVO.
In addition to serving as an editor for Pharmaceutical Research, Dr. Kompella served as an editor for Clinical Research and Regulatory Affairs and currently serves as the Editor-in-Chief for the journal Expert Opinion on Drug Delivery and as an Associate Editor for the Journal of Ocular Pharmacology and Therapeutics.

Tonglei Li, Editor 

Tonglei Li is a professor in the Department of Industrial and Physical Pharmacy at Purdue University. He started his academic career at the University of Kentucky in 2002. In 2012, he joined the faculty at Purdue’s West Lafayette campus. His research interests include solid-state organic chemistry, computational chemistry, drug delivery, and pharmacometrics. His group has worked toward understanding intermolecular interactions in organic crystals with density functional theory and electronic calculations, and it has tried to uncover the phase transition behaviors of organic materials with combined experimental and computational approaches. His work on developing drug nanocrystals has further aligned his focus toward predicting therapeutic kinetics of drug products with multiscale computation and simulation.
Dr. Li obtained his Ph.D. from Purdue University. He is currently the Associate Dean for Graduate Programs in the College of Pharmacy. He also holds the inaugural Allen Chao Endowed Chair in the College. Dr. Li has actively participated in various AAPS activities and became a Fellow in 2013.

Hanns-Christian Mahler, Editor 

Hanns-Christian Mahler is currently Head of Drug Product Services at Lonza AG, Basel, Switzerland. Prior to this position, he was working at Roche, Basel, Switzerland, as Head of Pharmaceutical Development and Supplies, Biologics EU. Before joining Roche, he worked at Merck KGaA, Darmstadt, Germany, as Principal Scientist in Pharmaceutical Development and CMC team leader for a successful antibody product launch.
He studied pharmacy and received his Ph.D. in toxicology from the School of Pharmacy, University of Mainz, Germany and completed his habilitation in pharmaceutical technology in 2010 at the University of Frankfurt/Main, Germany. Dr. Mahler is also Professor at the University of Frankfurt, Germany, and adjunct faculty member and lecturer at the University of Basel, Switzerland.
His industrial and scientific experience include formulation development of parenteral dosage forms including biologics, primary packaging development of injectables, drug delivery, sterile and aseptic drug product manufacturing (preclinical and clinical phase 1-3), process development, process characterization and validation, transfer to and support of commercial drug product sterile production. His research interests focus on stability, analysis, and processing of protein formulations. He is specifically interested in protein aggregation; particle formation and analysis; the behavior, degradation and analysis of surfactant; the interaction of proteins and excipients with processing material; and the human/user interface of parenteral drug products. Dr. Mahler has published numerous manuscripts, review articles, and book chapters; he has co-edited two books, and is co-inventor fn numerous patents. Dr. Mahler has been actively involved in the American Association of Pharmaceutical Scientists (AAPS) and was elected to be an AAPS Fellow in 2013. He also serves on the Editorial Advisory Board of the Journal of Pharmaceutical Sciences.

Tamara Minko, Editor 

Tamara Minko is a Distinguished Professor and Chair of the Department of Pharmaceutics at Rutgers, The State University of New Jersey. She is also a member of the Rutgers Cancer Institute of New Jersey and Environmental and Occupational Health Science Institute.
Her current research interests include nanotechnology; drug delivery; personalized nanomedicine; biopharmaceutics; molecular targeting; antisense oligonucleotides, siRNA, and peptide delivery; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs; bioimaging; preclinical evaluation of new therapeutics; and modulation of cell death mechanisms during hypoxia. Dr. Minko is author or coauthor of more than 400 publications (peer-reviewed papers, book chapters, conference proceedings, and patents). Many of her papers are well cited and published in prestigious journals with high impact factors.
Dr. Minko is an elected Fellow of three organizations: the Controlled Release Society (CRS), the American Association of Pharmaceutical Scientists (AAPS), and the American Institute for Medical and Biomedical Engineering (AIMBE). She is the recipient of numerous awards including the 2015 New Jersey Health Foundation Excellence in Research Award. She is a member of the editorial boards of 12 scientific journals and a member of Study Sections at the National Institutes of Health (NIH), Department of Defense, the American Heart Association, and other national and international review panels. Her research is supported by grants from NIH, the National Science Foundation, and other national and international sources.

Joseph Nicolazzo, Editor, Reviews and Theme Issues 

Joseph Nicolazzo
Joseph Nicolazzo graduated with a PhD in 2005 from Monash University (Australia) where he assessed the effect of various penetration enhancers on drug delivery through the buccal mucosa. After a post-doctoral position at the Centre for Drug Candidate Optimisation, Dr. Nicolazzo joined the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, as a Lecturer (2007), and he is now a Senior Lecturer (2013) there. Although he has some continuing interest in buccal mucosal drug delivery, his main research focus is on central nervous system (CNS) drug delivery and the role of drug transporters at the blood-brain barrier (BBB) in facilitating and limiting drug access into the CNS. Using in vitro, in situ, and in vivo methods Dr. Nicolazzo’s research group is also investigating how drug transport across the BBB alters in various disease states, including Alzheimer’s disease and systemic inflammation, and his group is also exploring the involvement of dysfunctional BBB transport proteins in the brain parenchymal accumulation of β-amyloid. His research has been funded by the National Health and Medical Research Council of Australia and various Australian philanthropic bodies. He received the Faculty of Pharmacy and Pharmaceutical Sciences Young Investigator Award in 2009, an Early Career Research Award in 2013, and an International Pharmaceutical Federation (FIP) Award of Recognition in 2014. Dr. Nicolazzo is Treasurer of the Australasian Pharmaceutical Science Association and an Editorial Board Member for Pharmaceutical Research, Journal of Pharmaceutical Sciences, and Frontiers in Drug Metabolism and Transport.

James. E. Polli, Editor 

Polli, Author
James E. Polli is Professor and Ralph F. Shangraw/Noxell Endowed Chair in Industrial Pharmacy and Pharmaceutics at the University of Maryland School of Pharmacy. He is also co-Director of the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), an FDA-funded collaborative agreement with the Agency, and Director of the online MS in Regulatory Science program (www.pharmacy.umaryland.edu/regulatoryscience). Dr. Polli’s research interest revolves around the performance and pharmaceutical quality of orally administered medicines. His two main research interests are: 1) maximizing oral bioavailability through formulation and chemical approaches and 2) developing public quality standards for oral dosage forms. He has published in the areas of dissolution, drug intestinal permeability, transporter substrate requirements, prodrug design, oral bioavailability, in vitro-in vivo correlation, and bioequivalence.

Ikumi Tamai, Editor 

Ikumi Tamai is currently a Professor and Chair of the Department of Membrane Transport and Biopharmaceutics, Faculty of Pharmaceutical Sciences at Kanazawa University in Japan. He received his B.S. degree from Kanazawa University in 1982 and his Ph.D. degree in Pharmaceutical Sciences from the University of Tokyo. He started his research on carrier-mediated transports of drugs and pharmacokinetics with Professor Akira Tsuji at Kanazawa University. Beginning in 1989, Dr. Tamai spent two years as a research associate at the University of Chicago and the University of Michigan for studies on P-glycoprotein and intestinal absorption and transporters, respectively. Then, he was appointed as assistant professor and associate professor in Kanazawa University. In 2002, he moved to the Tokyo University of Science as a Professor in the Faculty of Pharmaceutical Sciences, and in 2008, he moved to Kanazawa University. His research has focused on membrane transporters that might determine pharmacokinetic properties and efficacy and toxicity of drugs as well as physiological compounds. He has contributed to research on: (1) the role of P-glycoprotein as the BBB since 1992, (2) the characterization of PEPT1 and intestinal absorption of peptide mimetics since the middle of the 1980s, (3) molecular cloning and physiological and pharmacological roles of OCTNs since 1997, and (4) the roles of OATP transporters for intestinal absorption as well as hepatic disposition of drugs since 2000. He also has been studying membrane transports of physiological compounds such as uric acid, carnitine, and other small molecular nutrients that would be biomarkers. He has published more than 300 papers including original and review articles on transporter-related research. He served as a council member of ISSX and JSSX and Editor-in-Chief of Drug Metabolism and Pharmacokinetics (DMPK) and Editor for Biological and Pharmaceutical Bulletin (BPB). He currently is an Associate Editor for Biopharmaceutics and Drug Disposition (BDD) and is a member of the Editorial Board of Drug Metabolism and Disposition, Molecular Pharmaceutics, and the Journal of Pharmaceutical Sciences.

Christine Vauthier, Editor 

Christine Vauthier
Christine Vauthier is Director of Research at the Centre National de la Recherche Scientifique (CNRS). She received her Ph.D. in polymer chemistry in 1986 from the University Louis Pasteur at Strasbourg, France. She joined the University of Paris South, Faculty of Pharmacy in 1987 as a research assistant. During her career, she was a visiting scientist at the Center for Chemical Controlled Delivery, University of Utah, USA and at the Federal University of Pernambuco, Recife, Brazil. Currently, she is at the Institut Galien Paris Sud, UMR CNRS 8612, Université Paris Sud. Her research concentrates on the interface between the physico-chemistry of polymer colloids and the conception of nanomedicines for mucosal and intravenous administration of drugs including antisense oligonucleotides and siRNA. Starting with the characterization of polymer nanoparticles, her main interest is the understanding of the interactions of nanomedicines with biological systems. Dr. Vauthier is an author and coauthor of more than 100 research papers and more than 20 review papers and book chapters on nanoparticle preparation and characterization methods and the application of nanoparticles as drug delivery systems. She has presented more than 100 communications at invited conferences. She serves as an editor for Pharmaceutical Research.

Ernst Wagner, Editor 

Ernst Wagner has been a Professor of Pharmaceutical Biotechnology at Ludwig-Maximilians-Universität (LMU) of Munich since 2001, and he is a member of the Center for Nanoscience (CeNS). He coordinates the area of biomedical nanotechnologies of the cluster of excellence Nanosystems Initiative Munich (NIM). Dr. Wagner received a Ph.D. in organic chemistry from the Technical University of Vienna. After a postdoctoral stay at the ETH in Zurich, he became group leader at the Institute of Molecular Pathology and the Vienna University Biocenter, developing synthetic gene transfer systems. In parallel, from 1992 to 2001 he was Director for Cancer Vaccines at Boehringer Ingelheim Austria, where he developed the first polymer-based clinical gene therapy study in 1994. Dr. Wagner has written more than 360 publications and has more than 20 patents. In addition to serving as an Editor of Pharmaceutical Research, he is an Associate Editor of the Journal of Gene Medicine, board member of the German Society for Gene Therapy, committee member of the American Society ASGCT, and member of the Board of Scientific Advisors of the Controlled Release Society. He was an Honorary Professor for Biopharmaceutical Sciences at Utrecht University in 1996 and Fudan University Key Laboratory (Shanghai) in 2012-2013, and he has been Honorary Guest Professor at Sichuan University (Chengdu) for 2014-2017.

Yuhong Xu, Editor 

Yuhong Xu
Yuhong Xu is a Distinguished Professor of Pharmaceutics at Shanghai Jiaotong University. She is also a member of the National Collaborative Innovation Center for Translational Medicine in Shanghai. Her research activities have focused on the development of novel drug formulations and targeted delivery systems. She has worked on various liposome and nanoparticle formulations of cancer therapeutics, vaccine delivery systems, siRNA and gene delivery, and molecular imaging probes. She has authored and coauthored more than 100 papers in peer-reviewed scientific journals and granted more than 20 patents. She is the recipient of the NSFChina Outstanding Young Scientist Grant and the Henry Fok Young Investigator Award.
Dr. Xu received her B.S. in Electrical Engineering (1990) from Peking University and Ph.D. in Biophysical Sciences (1996) from the State University of New York at Buffalo. From 1993 to 1996 she was a postgraduate researcher at the University of California San Francisco. From 1996 to 2000, she worked in industry, first at Chiron Corporation as a postdoctoral researcher and then at Merck Research Laboratories as a senor scientist, both in the area of drug formulations. She returned to China in 2000 and joined Shanghai Jiaotong University (SJTU) as a full professor and PI of the Molecular Pharmaceutics Lab. She took a sabbatical leave during 2009-2010 and spent a year at GSK Shanghai Research Center as the director of Translational Research.
Dr. Xu has been elected as a Pharmaceutics Committee Member of the Chinese Pharmaceutical Association and appointed as an External Consulting Panel member for the Chinese sFDA Center for Drug Evaluation. She also serves as an editor for Pharmaceutical Research, an associate editor for the Journal of Liposome Research, and an editorial board member for the Asian Journal of Pharmaceutical Sciences.

Dr. Iñaki F. Trocóniz  

P_A55924_11095 Dr_95x120px
Dr. Iñaki F. Trocóniz is Professor of Biopharmaceutics and Pharmacokinetics in the Department of Pharmacy and Pharmaceutical Technology, of the School of Pharmacy and Nutrition at the University of Navarra, Pamplona (Spain).
He finished the Pharmacy studies in 1988 and got his Ph D degree in pharmacokinetics in 1991. During the periods 1991-93, 97, and 98, Dr. Trocóniz has occupied postdoctoral research positions in the University of California at San Francisco (USA), University of Uppsala (Sweden), and Eli & Lilly (UK), respectively.
Currently he is leading the research group in Pharmacometrics and Systems Pharmacology at the University of Navarra. His main research interests include development of mechanistic population pharmacokinetic/pharmacodynamics/disease models, and optimal control approaches applied in drug development and personalized medicine covering the therapeutic areas of (immune-) oncology, auto-immune diseases, gene therapy, pain, and rare diseases.
He has published over one hundred thirty articles in peer reviewed journals, and is currently supervising several research projects sponsored with funds from the government and drug companies. Dr. Trocóniz was awarded by the EUFEPS with the Giorgio Segré prize in pharmacokinetics/pharmacodynamics, and is the Pharmacometrics section editor of Pharmaceutical Research.

Read this Journal on Springerlink

For authors and editors

  • Journal Citation Reports®
    2017 Impact Factor
  • 3.335
  • Aims and Scope

    Aims and Scope


    Pharmaceutical Research, an official journal of the American Association of Pharmaceutical Scientists, is committed to publishing novel research that is mechanism-based, hypothesis-driven and addresses significant issues in drug discovery, development and regulation. Current areas of interest include, but are not limited to:

    • (pre)formulation engineering and processing
    • computational biopharmaceutics
    • drug delivery and targeting
    • molecular biopharmaceutics and drug disposition (including cellular and molecular pharmacology)
    • pharmacokinetics, pharmacodynamics and pharmacogenetics

    Research may involve nonclinical and clinical studies, and utilize both in vitro and in vivo approaches. Studies on small drug molecules, pharmaceutical solid materials (including biomaterials, polymers and nanoparticles) biotechnology products (including genes, peptides, proteins and vaccines), and genetically engineered cells are welcome.

    Pharmaceutical Research publishes twelve issues a year.

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors

    Instructions for Authors


  • Information about publishing with Spring...
  • Author Academy: Training for Authors
  • Author Services
  • Copyright Information

    Copyright Information


    Copyright Information

    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to Springer (respective to owner if other than Springer) becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to Springer effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author's accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via link.springer.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher (respective the copyright owner if other than Springer). The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on link.springer.com or on springerimages.com and click on the permissions link or go to copyright.com, then enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.

    © Springer Science+Business Media New York

Services for the Journal

Alerts for this journal


Get the table of contents of every new issue published in Pharmaceutical Research.